Erythrocyte transport efficacy of human blood: A rheological point of view

European Journal of Clinical Investigation

Volumn 35, Issue 11, 2005, Pages 687-690

  Bogar, L ^a   Juricskay, I ^a   Kesmarky, G ^a   Kenyeres, P ^a   Toth, K ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Blood viscosity; Haematocrit; Haemorheology; Hyperlipidaemia; Raynaud's disease

Indexed keywords

HEMOGLOBIN;

ADULT; AGED; ANEMIA; BLOOD RHEOLOGY; BLOOD VISCOSITY; CARDIOVASCULAR RISK; CELL TRANSPORT; CONTROLLED STUDY; EPIDEMIOLOGICAL DATA; ERYTHROCYTE; FEMALE; HEMATOCRIT; HUMAN; HUMAN CELL; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; OXYGEN AFFINITY; POLYCYTHEMIA; PRIORITY JOURNAL; RAYNAUD PHENOMENON; REVIEW; SHEAR RATE; VISCOMETER;

ADOLESCENT; ADULT; AGED; BLOOD VISCOSITY; ERYTHROCYTES; FEMALE; HEMATOCRIT; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; NORMAL DISTRIBUTION; RAYNAUD DISEASE; RETROSPECTIVE STUDIES;

EID: 27844507479     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2005.01562.x     Document Type: Review

References (18)

1. Reinecke H, Trey T, Wellmann J, Heidrich J, Fobker M, Wichter T et al. Haemoglobin-related mortality in patients undergoing percutaneous coronary interventions. Eur Heart J 2003;24:2142-50.
2. Danesh J, Collins R, Peto R, Lowe GDO. Haematocrit, viscosity, erythrocyte sedimentation rate: meta-analyses of prospective studies of coronary heart disease. Eur Heart J 2000;21:515-20.
3. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease. JAMA 1998;279:1477-82.
4. Dormandy JA. The red cell as a risk factor in circulatory diseases. Adv Exp Med Biol 1984;164:151-68.
5. Forconi S, Pieragalli D, Guerrini M, Galigani C, Cappelli R. Primary and secondary blood viscosity syndromes and syndrome associated with blood hyperviscosity. Drugs 1987;33:19-26.
6. Le Devehat C, Khodabandehlou T. Transcutaneous oxygen pressure and hemorheology in diabetes mellitus. Int Angiol 1990;9:259-62.
7. Poli KA, Tofler GH, Larson M, Evans JC, Sutherland PA, Lipinska I et al. Association of blood pressure with fibrinolytic potential in the Framingham offspring population. Circulation 2000;101:264-9.
8. Lowe GDO, Forbes CD. Rheology of Cardiovascular Disease. Boca Raton, USA: CRC Press; 1988.
9. Höffkes HG, Ehrly AM. Optimal hematocrit in patients with intermittent claudication. Exercise induced muscle tissue oxygen pressure after stepwise isovolemic hemodilution. Clin Hemorheol 1992;12:321-7.
10. Chien S, Usami S, Taylor HM, Lundberg JL, Gregersen MI. Effect of hematocrit and plasma proteins on human blood rheology at low shear rates. J Appl Physiol 1966;21:81-7.
11. Stadler AA, Zilow EP, Linderkamp O. Blood viscosity and optimal hematocrit in narrow tubes. Biorheol 1990;27:779-88.
12. Dupuy-Fons C, Brun JF, Quere I, Bardet L, Janbon C. Rheology and occlusive arterial disease of the legs (French). J Mal Vasc 1996;21:165-70.
13. Brun JF, Bouchahda C, Chaze D, Benhaddad AA, Micallef JP, Mercier J. The paradox of hematocrit in exercise physiology: which is the 'normal' range from an hemorheologist viewpoint? Clin Hemorheol Microcirc 2000;22:287-303.
14. Ernst E, Matrai A. Zum Thema 'optimaler Hämatokrit' - Rationale der Hämodilutionstherapie. Herz Kreislauf 1983;9:409-15.
15. Linderkamp O, Meiselman HJ, Wu PYK, Miller FC. Blood and plasma viscosity and optimal hematocrit in the normal newborn infam. Clin Hemorheol 1981;1:575-84.
16. Gaetghens RJ, Kreutz F, Albrecht KH. Optimal hematocrit for canine skeletal muscle during rhythmic isotonic exercise. Eur J Appl Physiol 1979;41:27-39.
17. Hirakata H, Kanai H, Fukuda K, Tsuruya K, Ishida I, Kubo M et al. Optimal hematocrit for the maximum oxygen delivery to the brain with recombinant human erythropoietin in hemodialysis patients. Clin Nephrol 2000;53:354-61.
18. Koscielny J, Latza R, Pruss A, Kiesewetter H, Jung F, Meier C et al. Hypervolume trie hemodilution with HES 100/0.5 10% in patients with peripheral arterial occlusive disease (Fontaine, stage II): an open clinical and pharmacological phase IV study. Clin Hemorheol Microcirc 2000;22:53-65.